Home › Therapeutic areas › Immunology › Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (15 companies)
Companies with an active program in Systemic Lupus Erythematosus.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $26.0M | 8 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $256M | 10 |
| ALMS | Alumis | DermatologyImmunology+1 | 2 | Phase 3 | $628M | 5 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $290M | 12 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 2 | $220M | 8 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $249M | 9 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 2 | Phase 2 | $574M | 8 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 2 | NDA Submitted | $602M | 10 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $124M | 10 |
| INAB | IN8bio | ImmunologyOncology | 1 | Phase 1 | $8.9M | 4 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 1 | Phase 2 | $10.4B | 5 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.23B | 11 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $89.6M | 8 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.88B | 11 |
No companies match.